# GHK-Cu Dosage in Published Research: Protocols, Routes, and Chemistry

> GHK-Cu dosage in published research ranges from 10^-12 M in fibroblast cultures to 0.2–2 mg/kg IP in animal models. Topical concentrations 0.1–3%. Reconstitution chemistry, stability, and storage explained.

## GHK-Cu Dosage in Published Research

GHK-Cu is a research peptide compound without an FDA-approved drug indication for any route of administration. No validated human systemic dosing protocol exists in the peer-reviewed literature.

**Human topical studies.** Topical GHK-Cu concentrations in published human cosmetic and dermatological studies range from 0.1% to 3%. The Badenhorst (2016) nanocarrier wrinkle study did not fully disclose concentration; the ALAVAX hair trial used 50–100 mg/mL of the GHK peptide complex [6][18].

**Human clinical pharmacokinetics.** No formal Phase I human pharmacokinetic study for systemic GHK-Cu has been registered on ClinicalTrials.gov or published in peer-reviewed literature. The plasma half-life after intravenous administration is estimated at approximately 0.5–1 hour based on rapid peptidase degradation kinetics in plasma.

**Animal intraperitoneal studies.** The lung protection studies used GHK-Cu at 0.2, 2, and 20 μg/g/day IP in C57BL/6J mice [9]. The pulmonary fibrosis studies used 2.6, 26, and 260 μg/mL/day IP on alternating days from day 4 to day 21 [8]. The skeletal muscle studies used 0.2 and 2 mg/kg IP in mice [10].

**Animal intranasal studies.** The aging-mouse cognitive study used GHK-Cu at 15 mg/kg/day intranasal for 8 weeks in 20-month-old mice [15].

**In-vitro cell studies.** Fibroblast collagen stimulation was measured from 10^-12 to 10^-9 M in cell culture medium [1].

## GHK-Cu Dosing Ranges in Animal and Human Studies

| Species / Model | Route | Dose Range | Study Focus |
|---|---|---|---|
| Human fibroblasts (in vitro) | Cell culture | 10^-12 – 10^-9 M | Collagen synthesis [1] |
| Human skin (ex vivo) | Topical | 0.1–3% in formulation | Penetration, collagen [13][18] |
| Human (RCT, topical) | Topical | 50–100 mg/mL (ALAVAX complex) | Hair growth [6] |
| Mouse C57BL/6J (IP) | Intraperitoneal | 0.2, 2, 20 μg/g/day | Lung protection [9] |
| Mouse C57BL/6 (IP) | Intraperitoneal | 2.6, 26, 260 μg/mL/day | Pulmonary fibrosis [8] |
| Mouse (IP) | Intraperitoneal | 0.2, 2 mg/kg | Skeletal muscle [10] |
| Mouse aging (intranasal) | Intranasal | 15 mg/kg/day for 8 wk | Cognitive aging [15] |
| Mouse (topical microemulsion) | Topical | CaT-ME formulation | Hair follicle [7] |

The dose ranges are not directly comparable across routes, species, and tissue targets.

## GHK-Cu Half-Life and Pharmacokinetics

Formal published pharmacokinetic data for GHK-Cu after IV or subcutaneous administration in humans does not exist. The plasma half-life after IV administration is estimated at approximately 0.5–1 hour.

Topical pharmacokinetics are better characterized. In-vitro human skin permeation data shows the stratum corneum accumulating 438-fold over baseline copper levels and the epidermis 165-fold over 48 hours, with approximately 2% total penetration through to the dermis [13].

## Why GHK-Cu Solution Appears Blue: The Chemistry Explained

Reconstituted GHK-Cu solution is blue-violet in color. This is expected and indicates the compound is intact. The color arises from the Cu(II) d-orbital electronic absorption — a characteristic absorption band in the 500–600 nm range [22].

A color shift after reconstitution indicates a problem:
- **Green or brown.** Indicates Cu(II) oxidation to Cu(III) or precipitation. The compound has degraded [22].
- **Yellow or colorless.** Could indicate very high dilution, incorrect reconstitution, or loss of copper during storage.

Practical stability notes: optimal storage of lyophilized GHK-Cu is at -20°C, protected from moisture and light — stable for 12–24 months. Reconstituted solution should be stored at 4°C and used within 2–4 weeks [22].

## Reconstituted GHK-Cu Color Changes: Oxidation and Stability

Brown or green coloration after reconstitution indicates copper oxidation from Cu(II) to Cu(III) or precipitation. Ascorbic acid (Vitamin C) at pH 2.5–3.5 will reduce Cu(II) to Cu(I) and destroy both the copper peptide and the ascorbic acid simultaneously [22]. Research formulation protocols use separate application windows.

## References

[1] Maquart FX et al. FEBS Letters. 1988;238(2):343-346. https://pubmed.ncbi.nlm.nih.gov/3169264/
[6] Lee WJ et al. Annals of Dermatology. 2016;28(4):438-443. https://pmc.ncbi.nlm.nih.gov/articles/PMC4969472/
[7] Liu T et al. Bioactive Materials. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10643103/
[8] Hou G et al. Front Pharmacol. 2017;8:904. https://pmc.ncbi.nlm.nih.gov/articles/PMC5733019/
[9] Zhang Q et al. Front Mol Biosci. 2022;9:925700. https://pmc.ncbi.nlm.nih.gov/articles/PMC9354777/
[10] Deng M et al. J Cachexia Sarcopenia Muscle. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10235902/
[13] Hostynek JJ et al. Inflammation Research. 2010. https://pmc.ncbi.nlm.nih.gov/articles/PMC3016279/
[15] Tucker M et al. Aging Pathobiol Ther. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10680828/
[18] Badenhorst T et al. J Aging Sci. 2016;4:166.
[22] Ogorek K et al. Molecules. 2025;30(1):136. https://pmc.ncbi.nlm.nih.gov/articles/PMC11721469/

---

Plain-language summaries of the peer-reviewed copper-peptide record — cited study by study, chapter by chapter, sold by no one.